Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression

By sjmartinez • September 13, 2023

Topp BG, Channavazzala M, Mayawala K, De Alwis DP, Rubin E, Snyder A, Wolchok JD, Ribas A. Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression. Cancer Cell. 2023 Sep 11;41(9):1680-1688.e2. doi: 10.1016/j.ccell.2023.08.004. PMID: 37699333.

Tags: clear-cell renal cell carcinoma, gastric cancer, Head and neck squamous cell carcinoma, Hematology/Oncology, melanoma, Non-small cell lung cancer, pembrolizumab, postprogression response, Publications, urothelial carcinoma

Doxorubicin, bleomycin, vinblastine, and dacarbazine for Hodgkin lymphoma: Real-world experience from a Los Angeles County hospital

Chao E, Marshalek JP, Yashar D, Tomassetti S. Doxorubicin, bleomycin, vinblastine, and dacarbazine for Hodgkin lymphoma: Real-world experience from a Los Angeles County hospital. SAGE[...]

Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence

Conforti F, Merlo F, Pala L, Canzian J, Tinterri B, De Pas T, Locatelli M, Dickerson JC, Cortes J, Slamon DJ, Gelber R, Bagnardi V.[...]

Outpatient axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma: ZUMA-24 primary analysis

Leslie LA, Baird JH, Flinn IW, Tees M, Hoda D, Deol A, Young P, McClune B, Varadarajan I, Essell J, Fanning S, Simmons G, Clark[...]